Skip to main content
Fig. 2 | Infectious Agents and Cancer

Fig. 2

From: Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

Fig. 2

Figure represents the frequency (expressed as absolute number) of all adverse drug reactions reported in all patients during treatment follow-up. They are classified according to organ for each single antiviral schedule. According to our findings we had that patients undergoing schedule Simeprevir/Sofosbuvir had a higher frequency of skin disorders, while anaemia and asthenia were most frequently observed in those undergoing Sofosbuvir/Ledipasvir/Ribavirin treatment. Of note the Central Nervous System adverse events related to mood alteration and sleep disorders in those patients under Daklinza/Sofosbuvir antiviral schedule

Back to article page